| abstract |
The present invention provides a biomarker of an immunomodulatory effect in human treatment using an anti-CD200 antibody. The present disclosure relates to anti-CD200 antibodies (eg, modified anti-CD200 antibodies that have reduced or no effector function) and various diagnostic and therapeutic methods, such as desired Used in determining whether or not one or more antibodies have been administered to a human at a dose sufficient to induce the immunomodulatory effects of the subject in a human and / or to select an appropriate dosing schedule for the patient Related to biomarkers. [Selection] Figure 1 |